Dr. Bogdan Milojkovic serves on the Medical Advisory Board of the Texas Kidney Foundation (TKF), bringing together academic expertise, scientific innovation, and executive leadership to advance kidney health. As Chief Medical Officer and Global Director of Medical and Scientific Affairs at Nova Biomedical, the largest privately owned diagnostics company in the United States, he leads clinical strategy, research validation, and global education initiatives that shape the future of point-of-care testing and chronic disease detection.

Dr. Milojkovic has been instrumental in pioneering decentralized kidney health screening. Under his leadership, Nova Biomedical partnered with Carna Health to launch community-based pilot programs using fingerstick creatinine and eGFR testing. In Bermuda, this model revealed that nearly half of participants had chronic kidney disease—94% of whom were previously undiagnosed—demonstrating the power of accessible screening to transform public health outcomes.

Before his executive career, Dr. Milojkovic conducted groundbreaking neuroscience research at Yale University, publishing in leading journals such as Neuron and The Journal of Neuroscience. His work on dendritic integration, calcium dynamics, and neuronal signaling advanced understanding of how the brain processes learning and memory. He has since applied this scientific rigor to diagnostics, building technologies and strategies that improve early disease detection worldwide.

As a physician-scientist, educator, and global medical leader, Dr. Milojkovic bridges the worlds of research, technology, and patient care. At TKF, he helps guide prevention-first strategies that make cutting-edge diagnostics available to underserved populations, ensuring that Texans benefit from innovation, early detection, and better outcomes in kidney health.